Biomarker Discovery in Non–Small Cell Lung Cancer: Integrating Gene Expression Profiling, Meta-analysis, and Tissue Microarray ValidationJohan Botling, Patrick Micke, Michael Bergqvist et al.|Clinical Cancer Research|2012Cited by 382
Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non‐small‐cell lung cancerPatrick Micke, Özlem Türeci|International Journal of Cancer|2014Cited by 132
Inconsistent results in the analysis of ALK rearrangements in non-small cell lung cancerJohanna Sofia Margareta Mattsson, Maria A. Svensson, Hans Brunnström et al.|BMC Cancer|2016Cited by 36
Prognostic impact of COX-2 in non-small cell lung cancer: A comprehensive compartment-specific evaluation of tumor and stromal cell expressionJohanna Sofia Margareta Mattsson, Miklós Gulyás, Bengt Bergman et al.|Cancer Letters|2014Cited by 29